PRESCRIBING FOR CHILDREN AND ADOLESCENTS

LEARNING RESOURCES

· Hilt, R. J., & Nussbaum, A. M. (2016).  DSM-5 pocket guide for child and adolescent mental health  Links to an external site. . American Psychiatric Association Publishing.

· Chapter 14, “Psychosocial Interventions”

· Chapter 15, “Psychotherapeutic Interventions”

· Chapter 16, “Psychopharmacological Interventions”Links to an external site.

· Thapar, A., Pine, D. S., Leckman, J. F., Scott, S., Snowling, M. J., & Taylor, E. A. (2015).  Rutter’s child and adolescent psychiatry (6th ed.). Wiley Blackwell.

· Chapter 43, “Pharmacological, Medically-Led and Related Treatments”

· Walden University. (n.d.).  Developing SMART goals  Links to an external site. . https://academicguides.waldenu.edu/ld.php?content_id=51901492Links to an external site.

· Zakhari, R. (2020).  The psychiatric-mental health nurse practitioner certification review manual. Springer.

· Chapter 5, “Psychopharmacology”

REQUIRES Media

· CriticalThinkRx. (2019, June 9).  Module 5:   Links to an external site. Specific drug classes: Focus on adverse effects Links to an external site.  [Video]. YouTube. https://youtu.be/Gbq6RnOsGKQLinks to an external site.

· CriticalThinkRx. (2019, June 9).  Module 2: Use of psychotropics with youth_prevalence and concerns  Links to an external site.  [Video]. YouTube. https://youtu.be/NRef-g4Ding

TO PREPARE

You are assigned to research on Disruptive Mood Dysregulation Disorder

· Research evidence-based treatments for your Disruptive Mood Dysregulation Disorder in children and adolescents. You will need to recommend one FDA-approved drug, one off-label drug, and one nonpharmacological intervention for treating this disorder in children and adolescents.

THE ASSIGNMENT (1–2 PAGES)

· Recommend one FDA-approved drug, one off-label drug, and one nonpharmacological intervention for treating Disruptive Mood Dysregulation Disorder in children and adolescents.

· Explain the risk assessment you would use to inform your treatment decision making. What are the risks and benefits of the FDA-approved medicine? What are the risks and benefits of the off-label drug?

· Explain whether clinical practice guidelines exist for this disorder and, if so, use them to justify your recommendations. If not, explain what information you would need to take into consideration.

· Support your reasoning with at least three scholarly resources, one each on the FDA-approved drug, the off-label, and a non-medication intervention for the disorder. Attach the PDFs of your sources.

MY RESEARCHED ARTICLES

Byrne, G., & Connon, G. (2021). The Use of Standard Parenting Management Training in Addressing Disruptive Mood Dysregulation Disorder: A Pilot Study.  Journal of Contemporary Psychotherapy,  51(3), 259–263. https://doi.org/10.1007/s10879-021-09489-5

Winters, D. E., Fukui, S., Leibenluft, E., & Hulvershorn, L. A. (2018). Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder.  Journal of Child & Adolescent Psychopharmacology,  28(5), 298–305. https://doi.org/10.1089/cap.2017.0124

Tapia, V., & John, R. M. (2018). Disruptive Mood Dysregulation Disorder.  Journal for Nurse Practitioners,  14(8), 573–578. https://doi.org/10.1016/j.nurpra.2018.07.007

Pan, P.-Y., Fu, A.-T., & Yeh, C.-B. (2018). Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study.  Journal of Child & Adolescent Psychopharmacology,  28(10), 682–689. https://doi.org/10.1089/cap.2018.0068

Rice, T., Simon, H., Barckak, D., Maiyuran, H., Chan, V., Hassan, Y., Tatum, J., & Coffey, B. J. (2019). Amantadine for Treatment of Disruptive Mood Dysregulation Disorder Symptoms.  Journal of Child & Adolescent Psychopharmacology,  29(8), 642–646. https://doi.org/10.1089/cap.2019.29172.bjc

Le, J., Feygin, Y., Creel, L., Lohr, W. D., Jones, V. F., Williams, P. G., Myers, J. A., Pasquenza, N., & Davis, D. W. (2020). Trends in diagnosis of bipolar and disruptive mood dysregulation disorders in children and youth.  Journal of Affective Disorders,  264, 242–248. https://doi.org/10.1016/j.jad.2019.12.018

Uran, P., & Kılıç, B. G. (2020). Family Functioning, Comorbidities, and Behavioral Profiles of Children With ADHD and Disruptive Mood Dysregulation Disorder.  Journal of Attention Disorders,  24(9), 1285–1294. https://doi.org/10.1177/1087054715588949

Linke, J., Kircanski, K., Brooks, J., Perhamus, G., Gold, A. L., & Brotman, M. A. (2020). Exposure-Based Cognitive-Behavioral Therapy for Disruptive Mood Dysregulation Disorder: An Evidence-Based Case Study.  Behavior Therapy,  51(2), 320–333. https://doi.org/10.1016/j.beth.2019.05.007

Mulraney, M., Schilpzand, E., Hazell, P., Nicholson, J., Anderson, V., Efron, D., Silk, T., & Sciberras, E. (2016). Comorbidity and correlates of disruptive mood dysregulation disorder in 6-8-year-old children with ADHD.  European Child & Adolescent Psychiatry,  25(3), 321–330. https://doi.org/10.1007/s00787-015-0738-9

Lin, Y.-J., Tseng, W.-L., & Gau, S. S.-F. (2021). Psychiatric comorbidity and social adjustment difficulties in children with disruptive mood dysregulation disorder: A national epidemiological study.  Journal of Affective Disorders,  281, 485–492. https://doi.org/10.1016/j.jad.2020.12.039